Close

Catalent To Debate Logistics Of Delivery And Transportation Of Cell And Gene Therapies At HPCLC

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

When Pharma Meets the Underworld: How Legitimate Drug Supply Chains and Illicit Drug Markets Collide

In today's global landscape, the intersection between legitimate pharmaceutical...

Pharma’s Philanthropic Scrutiny: Navigating Charity Commission Investigations in Healthcare Giving

In the healthcare sector, the intersection of pharmaceutical companies...

Role of Combination Products is on the Rise in Biopharma

In the dynamic world of today, role of combination...

Buyout of SpringWorks Brings Back Merck KGaA in the M&A Game

Merck KGaA’s long-standing courtship of SpringWorks Therapeutics has finally...

Catalent, a global leader in clinical supply services, announced that Ann McMahon, Program Director, Clinical Supply Services and Drug Product Technologies Integration, will participate in a panel session titled “ Cell and Gene Therapy Logistics ” at the upcoming Health and Personal Care Logistics Conference (HPCLC), to be held at the Gwen Hotel, Chicago.

The panel session, on Wednesday, Oct. 30 at 8:30 a.m., comes at a time when there is an increasing focus on individualizing patient care, and panelists will discuss the critical logistics of delivery and transportation as patient care changes; and as cell, gene and biologics therapies constitute an ever-increasing share of treatments. The panelists will also explore future transportation demands.

Ms. McMahon has over 17 years of experience in the pharmaceutical industry. Prior to joining Catalent, she was Manager, New Product Launch at West-Ward Pharmaceuticals, and also Boehringer Ingelheim. She holds a bachelor’s degree in biology/biochemistry from Ohio Northern University, Ada, Ohio; and a master’s degree in clinical pharmacology from the Ohio State University, Columbus, Ohio.

For further information, visit https://www.hpclcnet.org

Latest stories

Related stories

When Pharma Meets the Underworld: How Legitimate Drug Supply Chains and Illicit Drug Markets Collide

In today's global landscape, the intersection between legitimate pharmaceutical...

Pharma’s Philanthropic Scrutiny: Navigating Charity Commission Investigations in Healthcare Giving

In the healthcare sector, the intersection of pharmaceutical companies...

Role of Combination Products is on the Rise in Biopharma

In the dynamic world of today, role of combination...

Buyout of SpringWorks Brings Back Merck KGaA in the M&A Game

Merck KGaA’s long-standing courtship of SpringWorks Therapeutics has finally...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back